Search
for
Sort by
Research 31–60 of 71
- Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
- Neurological post‐acute sequelae of SARS‐CoV‐2 infection
- Early androgenetic alopecia as a possible indicator of diabetes mellitus and its link to cardiovascular risks: a cross-sectional study
- Exploring the Role of GLP‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
- Iron Deficiency in Immune-Mediated Inflammatory Skin Diseases: A Missing Link Between Systemic Inflammation, Immunometabolism, and Disease Burden
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Low-dose oral minoxidil for androgenetic alopecia is not associated with blood pressure changes in patients also taking other antihypertensive medications: A multi-center cohort study using TriNetX
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- 0414 Cumulative atopic disease burden is associated with increased risk of alopecia areata: A TriNetX cohort study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Broad laboratory testing does not show utility for telogen effluvium: a retrospective analysis of 22-million laboratory results using TriNetX
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-Term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-Matched Observational Study
- LB892 Assessing the risk of alopecia areata development in patients with seasonal and food allergies: a matched population-level analysis
- Simultaneous Versus Delayed Initiation of Spironolactone and Low‐Dose Oral Minoxidil: Adverse Event Rates in a Retrospective Cohort Study
- 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
- LB923 A matched cohort study evaluating the risk of keloid development in alopecia areata patients
- Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Beyond hair loss: Exploring the psychiatric burden of alopecia areata in a large cohort
- 0413 IL-17 Inhibitors vs. methotrexate in preventing new-onset psoriatic arthritis in psoriasis patients: a retrospective population-level analysis
- Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study
- Androgenetic alopecia is not associated with increased incidence of cardiovascular disease risk factors: A retrospective cohort study
- 61131 Impact of Low-Dose Oral Minoxidil on Blood Pressure in Androgenetic Alopecia Patients Concomitantly Taking Antihypertensive Medications: A Multi-Center Cohort Study
- 0415 Spironolactone treatment for dermatologic conditions and blood pressure changes in hypertensive patients on concomitant antihypertensive therapy